QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
This study is to describe the quality of life of Korean patients with early
 relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon
 with several validated questionnaires.
Inclusion Criteria:

 -  Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis
 according to Poser or McDonald criteria, starting Betaferon treatment, including
 patients switching from other DMDs

 -  Patients who signed informed consent form

 Exclusion Criteria:

 -  Age lower than 18